Literature DB >> 32380906

Emergence of Escherichia coli ST131 Causing Urinary Tract Infection in Western Asia: A Systematic Review and Meta-Analysis.

Alireza Jafari1, Siavash Falahatkar1, Kourosh Delpasand2, Hoda Sabati3, Hadi Sedigh Ebrahim-Saraie4.   

Abstract

Escherichia coli sequence type (ST) 131 is considered a high-risk pandemic clone and frequently extended-spectrum β-lactamase (ESBL)-producing clone that is strongly associated with the global dissemination of CTX-M-15 type. The emergence of ST131 has become a public health threat because this clonal group typically exhibits multiple virulence factors and antimicrobial resistance. Therefore, this study aimed to analyze the literature published on the estimation of the prevalence of clone ST131 among E. coli strains isolated from patients with urinary tract infections in western Asia. A systematic search was carried out to identify eligible articles in the Web of Science, PubMed, Scopus, Embase, and Google Scholar electronic databases from January 2010 to December 2018. Next, 13 articles meeting the inclusion criteria were selected for data extraction and analysis by Comprehensive Meta-Analysis Software. The included studies were conducted in Iran, Jordan, Kuwait, Pakistan, Saudi Arabia, Turkey, and Yemen. In all studies, the pooled prevalence of ST131 was 24.6% (95% CI: 13.5%-40.4%) in wild type isolates, 42.7% (95% CI: 32.5%-53.5%) among ESBLs-producing isolates, and 64.8% (95% CI: 36%-85.5%) among multiple-drug resistant (MDR) isolates. Moreover, the prevalence of ST131 isolates carrying CTX-M-15 type was 68% (95% CI: 48.4%-82.8%). Our study indicated the high prevalence of broadly disseminated ST131 clone among MDR and ESBLs isolates in western Asia. Moreover, O25b was the predominant ST131 clone type, which was mostly associated with CTX-M-15 type.

Entities:  

Keywords:  Asia; CTX-M-15; ESBL; Escherichia coli; ST131

Year:  2020        PMID: 32380906     DOI: 10.1089/mdr.2019.0312

Source DB:  PubMed          Journal:  Microb Drug Resist        ISSN: 1076-6294            Impact factor:   3.431


  6 in total

1.  Expansion of a Subset Within the C2 Subclade of Escherichia coli Sequence Type 131 (ST131) Is Driving the Increasing Rates of Aminoglycoside Resistance.

Authors:  Zoya Hojabri; Narges Darabi; Majid Mirmohammadkhani; Hamzeh Rahimi; Romina Hemmati; Zahra Saeedi; Kiarash Roustaee; Pimlapas Leekitcharoenphon; Omid Pajand; Frank M Aarestrup
Journal:  Open Forum Infect Dis       Date:  2020-09-08       Impact factor: 3.835

2.  Antimicrobial Resistance and Molecular Epidemiology of Escherichia coli From Bloodstream Infection in Shanghai, China, 2016-2019.

Authors:  Shuzhen Xiao; Chenyue Tang; Qian Zeng; Yilun Xue; Qing Chen; Erzhen Chen; Lizhong Han
Journal:  Front Med (Lausanne)       Date:  2022-01-10

3.  Molecular epidemiology of blaCTX-M gene-producing uropathogenic Escherichia coli among Iranian kidney transplant patients: clonal dissemination of CC131 and CC10.

Authors:  Mehrdad Halaji; Shahrzad Shahidi; Behrooz Ataei; Abdolamir Atapour; Awat Feizi; Seyed Asghar Havaei
Journal:  Ann Clin Microbiol Antimicrob       Date:  2021-09-08       Impact factor: 3.944

4.  Molecular determination of O25b/ST131 clone type among extended spectrum β-lactamases production Escherichia coli recovering from urinary tract infection isolates.

Authors:  Amin Khoshbayan; Rezvan Golmoradi Zadeh; Majid Taati Moghadam; Shiva Mirkalantari; Atieh Darbandi
Journal:  Ann Clin Microbiol Antimicrob       Date:  2022-08-04       Impact factor: 6.781

5.  Prevalence and distribution of extended-spectrum β-lactamase and AmpC-producing Escherichia coli in two New Zealand dairy farm environments.

Authors:  Rose M Collis; Patrick J Biggs; Sara A Burgess; Anne C Midwinter; Gale Brightwell; Adrian L Cookson
Journal:  Front Microbiol       Date:  2022-08-11       Impact factor: 6.064

6.  CTX-M-15 Positive Escherichia coli and Klebsiella pneumoniae Outbreak in the Neonatal Intensive Care Unit of a Maternity Hospital in Ha'il, Saudi Arabia.

Authors:  Mohammed Almogbel; Ahmed Altheban; Mohammed Alenezi; Khalid Al-Motair; Godfred A Menezes; Mohammed Elabbasy; Sahar Hammam; John P Hays; Mushtaq A Khan
Journal:  Infect Drug Resist       Date:  2021-07-23       Impact factor: 4.003

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.